Bringing specialist-level diagnostics, imaging, and therapeutics directly to patients wherever they are—from hospitals to care facilities to homes. Comprehensive wound management spanning diabetic foot ulcers, pressure injuries, venous ulcers, surgical wounds, burns, and traumatic wounds. Integrated with British NICE guidelines for risk stratification.
Based on NICE NG19 guidelines, ensuring appropriate care intensity matched to clinical risk and urgency.
Active ulceration, spreading infection, critical ischaemia, gangrene, or suspected acute Charcot arthropathy
Previous ulceration/amputation, renal replacement therapy, neuropathy + PAD, or multiple risk factors combined
Single risk factor: deformity OR neuropathy OR peripheral arterial disease
No risk factors present (no neuropathy, no PAD, no deformity beyond simple callus)
Mobile specialist teams deploy advanced diagnostics and therapeutics directly to hospitals, care facilities, and patient homes—eliminating transportation barriers and ensuring timely access to specialist care.
Mobile teams don't just deliver treatment—they build local capacity through hands-on education for facility staff, family caregivers, and patients.
Every component of the image-guided wound healing system is engineered for portability, enabling hospital-grade diagnostics and therapeutics at any location.
Clear performance standards at every tier ensure timely access, appropriate care intensity, and measurable outcomes.
Grounded in the 2026 Cell Host & Microbe landmark study (MIT/Singapore/Geneva), this protocol closes the loop between wound pH monitoring and targeted intervention. When E. faecalis produces lactic acid, wound pH rises above 7 — activating the immune suppression cascade. HealPath360 AI detects this biomarker and triggers a structured escalation response.
EVOSens integrated dressing changes color to bright blue, signalling wound pH >7 (alkaline). This visual alert is detectable by nurses, carers, or the patient — no specialist required at this stage.
AI dispatches community nurse or specialist for CureVision BacteriaScan within 24 hours. Porphyrin fluorescence maps bacterial distribution — confirming presence and location of E. faecalis and polymicrobial co-infection.
Fluorescence confirms lactic-acid-producing bacteria. AI cross-references wound pH, bacterial map, vascular status (MESI ABI/TBI), and healing trajectory to determine intervention intensity and select the optimal therapeutic combination.
100% medical-grade oxygen at 1.03–1.05 ATA disrupts the anaerobic environment that enables E. faecalis lactic acid production. 4 hrs/day × 4 days/week protocol. Restores immune macrophage function by reversing GPR81-mediated NF-κB suppression.
AI-guided debridement targets bacterial hotspots identified by CureVision fluorescence map. Ultrasonic energy disrupts biofilm matrix, removes devitalised tissue, and eliminates lactic acid-producing bacterial colonies with precision.
AI selects dressing based on wound size, pain level, and bacterial load. SAM™ PainGuard™ delivers 72-hour antimicrobial silver + controlled-release lidocaine for painful procedures. Microlyte® provides bioresorbable scaffold for chronic DFU closure (79% at 3 weeks).
eKare platform tracks pH normalisation (target <6.5), wound area reduction, and bacterial fluorescence response at each visit. If pH remains elevated after 72 hours, AI escalates to Tier 3 specialist review and considers systemic antibiotic stewardship consultation. All data feeds into the healing trajectory model for continuous protocol optimisation.
EVOSens dressing returns to normal colour (pH <6.5). CureVision confirms bacterial clearance. AI updates healing trajectory — patient returns to standard surveillance tier with continued monitoring. Wound closure pathway initiated.
Transform your wound care delivery model with integrated technology, specialist teams, and proven protocols that bring care directly to patients.